A Cohort Study to Evaluate Safety and Immunogenicity of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine (LVRNA012) in Participants Aged 18 Years and Over in China
Latest Information Update: 10 Jul 2023
At a glance
- Drugs LVRNA 012 (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Sponsors AIM Vaccine
Most Recent Events
- 15 Mar 2023 Planned End Date changed from 1 Mar 2024 to 1 Apr 2024.
- 15 Mar 2023 Planned initiation date changed from 1 Feb 2023 to 1 Apr 2023.
- 01 Dec 2022 Planned primary completion date changed from 1 Jan 2023 to 1 May 2023.